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SYNTHESIS AND CHARACTERIZATION OF A LONG-ACTING  
EMTRICITABINE PRODRUG FORMULATION 
 
Ibrahim M. Ibrahim, MBBS, PhD 
University of Nebraska Medical Center, 2019 
Supervisor: Howard E. Gendelman, MD 
The introduction of highly active antiretroviral therapy led to a paradigm shift in the 
management of HIV/AIDS changing a disease considered “a death sentence” to “a 
manageable chronic disease”. Nevertheless, challenges exist for successful treatment of 
HIV, including patient adherence to the complex daily regimens and the inability of current 
formulations to target viral sanctuaries. Introduction of nanoformulated antiretroviral 
therapy (ART) is a promising alternative to tackle these challenges. Our laboratory has 
been focusing on developing long-acting (LA) nanoformulated antiretrovirals and has 
succeeded in developing LA integrase inhibitors. However, challenges for this approach 
extend to a range of short-acting hydrophilic drugs, mainly nucleoside reverse 
transcriptase inhibitors (NRTIs). To this end, we developed a one-step synthesis scheme 
to create a hydrophobic ester prodrug of emtricitabine (FTC), an NRTI that is a key 
component of the initial ART and of a reported pre-exposure prophylaxis measure. The 
nanoformulation process was optimized to prepare poloxamer 407-encased nanocrystals. 
To eliminate HIV from the viral sanctuaries, macrophages were harnessed as “Trojan 
horses” for drug delivery and distribution to these difficult-to-reach sanctuaries. 
Nanoformulation of the FTC prodrug was facilitated by conjugating it to a long fatty acid 
chain, palmitoyl chloride. The resultant nanoparticles exhibited long-term stability, higher 
uptake and longer retention in macrophages, and these properties were translated into 
extended antiretroviral efficacy for 10 days. Moving this nanoformulation forward into 
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animal studies showed sustained FTC blood concentrations of more than 20-times its EC50 
at day 7 after a single intramuscular injection in rats, in contrast to undetectable levels 
following parent FTC injection. Furthermore, higher concentrations of FTC were observed 
in liver, spleen lymph nodes, and brain tissues. Interestingly, these results were mirrored 
by intracellular FTC triphosphate levels that were detectable for up to 10 days in vitro, and 
for 7 days in peripheral blood mononuclear cells (PBMCs) and in cells isolated from spleen 
and lymph nodes. We anticipate that this nanoformulation will further extend drug action 
in humans considering reported species differences in plasma esterase activities. Also, 
these improvements aided by medicinal chemistry unveils new opportunities for LA FTC 
formulation and for other NRTIs as well. These simplified manufacturing strategies hold 
promises for bringing LA ART closer to clinical translation.   
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1.1 HIV & AIDS Pandemic 
The extent of human immunodeficiency virus (HIV) infection is considerably 
variable between regions and countries. Although HIV has spread worldwide, African 
regions remains the most severely affected, with nearly 1 in every 25 adults is infected, 
and accounting for two thirds of the people infected with HIV globally [1].  According to 
statistical data available from UNAIDS for 2017, 36.9 million people were surviving with 
HIV. Of those, 1.8 million were newly infected, bringing the number of infected people 
since the start of the epidemic to 77.3 million. More concerning, only 21.7 million infected 
people had access to antiretroviral therapy (ART). Sadly, 940,000 people died due to 
AIDS-related illnesses including infections and cancers, bringing the number of deaths 
from HIV since the start of the epidemic to 35.4 million. At the end of 2017, there were 
21.3 billion US dollars available for the AIDS response in low- and middle- income 
countries. However, it is estimated that the fund required for the same cause will increase 
to 26.2 billion US dollars in 2020 [2]. 
1.2 HIV Biology 
 Acquired immunodeficiency syndrome (AIDS) was first reported by the United 
States Centers for Disease Control and Prevention (CDC) among homosexual men in 
New York and California in 1981 after observing increasing cases of rare diseases 
especially opportunistic infections and persistent lymphadenopathy [3, 4]. After a couple 
of years in 1983, the causative agent was discovered and named Human T Lymphocyte 
Virus (HTLV-III) until it acquired the current name as Human Immunodeficiency Virus 
(HIV) [5, 6]. HIV was found to be different in structure than other retroviruses. The HIV 
virion is about 100 nm in diameter. Its cone-shaped core consists of two copies of its 
ssRNA genome; the enzymes reverse transcriptase (RT), integrase, and protease; and 
several minor and major core proteins. The viral genome encodes 16 proteins that play 
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essential roles in the viral life cycle [7]. Advances in x-ray crystallography, cryo-electron 
microscopy, and cryo-electron tomography came together to study and describe the HIV 
envelope that facilitates viral interaction with host cell CD4 receptors and co-receptors  
CCR5 and CXCR4 [8-10]. The HIV envelope is a trimer containing three copies of non-
covalently associated heterodimers of gp120, the component that interacts with host cell 
receptors, and gp41, the transmembrane component essential for viral fusion with the 
cellular target membrane. Beside facilitating viral entry, the viral envelop plays a major 
role in evading host immune system. It also contributes to development of drug resistance 
against ART because of heterogeneity of the envelope that undergoes constant mutations 
of the envelope proteins [11]. 
1.3 HIV Pathogenesis 
 HIV infection in the host begins by the binding of the viral envelope to the CD4 
receptor and/or co-receptors CCR5 or CXCR4 on the cell surface. This interaction results 
in fusion of the viral and host cell membranes facilitating entry of the viral capsid core into 
the cytoplasm. Here, the viral RT begins to convert its RNA genome into double-stranded 
DNA. The core capsid then traffics into the host cell nucleus where it utilizes nuclear 
machinery to form progeny virions that are ultimately released to target new cells and 
propagate the infection (Figure 1) [12]. 
 HIV is a sexually transmitted disease that gains access through the mucosal 
membranes of the vagina, vulva, penis, and rectum. HIV is also spread by contact with 
infected blood, commonly among drug abusers through exchanging needles or syringes 
[13]. Although very low, risk of infection among health care providers also exists [14] with 
the risk estimated to be 0.3% after a needlestick and 0.09% after mucosal membrane 
exposure [15]. 
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 The course of infection with HIV is characterized by a long viral incubation period 
that may extend to more than 10 years before the onset of serious symptoms [16]. During 
the course of the disease, the patient generally starts suffering from flu-like illness and 
rash. With disease progression, as HIV continues replicating slowly, and infecting more 
CD4 lymphocyte and other cells, including monocytes and thymocytes [17, 18], the 
patient’s immune system deteriorates gradually. Normally, a healthy individual has CD4+ 
cell counts of 800-1200 cells/mm2. As CD4+ cells are destroyed by HIV, and the cell count 
drops to <500 cells/mm2, minor infections such as cold sores (herpes simplex) and vaginal 
candidiasis may occur. These infections are concerning but not life threatening. When 
CD4+ counts drop below 200 cells/mm2, the patient becomes vulnerable to serious 
opportunistic infections and the cancers that are the hallmarks of AIDS, the end stage of 
HIV (Figure 2) [19]. 
1.4 Current anti-HIV Therapy 
 Currently available ART is prescribed as a combination of drugs that target multiple 
stages of the HIV life-cycle. These drugs have significantly improved disease outcomes, 
a death sentence at one time, by reducing viral load and maintaining adequate CD4+ 
lymphocyte counts. Thus, decreased morbidity and mortality rates and limited viral 
transmission now render HIV a chronic disease. According to the International Antiviral 
Society-USA Panel, the recommended initial therapy includes two nucleoside reverse 
transcriptase inhibitors (NRTIs) and an integrase or a non-nucleoside reverse 
transcriptase inhibitor (NNRTI) [20]. However, additional classes of ART have been 
developed in response to emergence of drug resistance, drug-related toxicity, and other 
complications. These include, entry inhibitors, protease inhibitors, and integrase inhibitors. 
The chemical structures of different classes of drugs used in ART are illustrated in Figure 
3. 
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1.4.1 Entry inhibitors 
 As described earlier that viral entry into host cell requires binding of viral envelope 
proteins to a cellular receptor CD4 and a co-receptor, CCR5 or CXCR4. Entry inhibitors 
act by interfering with this interaction being the only class that acts before the infection. 
There are only two drugs approved in this class, maraviroc and enfuvirtide. Maraviroc acts 
by targeting host cell antagonizing CCR5 that binds viral gp120 envelope protein. 
Whereas enfuvirtide targets viral gp41 [21]. 
1.4.2 Nucleoside/nucleotide reverse transcriptase inhibitors 
 Several NRTIs were approved by US Food and Drug Administration (FDA) 
including abacavir, emtricitabine (FTC), lamivudine (3TC), and tenofovir. These drugs 
have to be activated in the cell to their active triphosphate metabolite to compete with 
intrinsic nucleosides for incorporation into the elongating viral DNA. Once incorporated, 
these nucleoside analogues lack a 3’-hydroxyl group that interacts with the next coming 
nucleoside terminating viral RT; thus, DNA synthesis. NRTIs are generally well tolerated; 
however, most commonly reported toxicities are ascribed to mitochondria as NRTIs are 
capable of inhibiting mitochondrial DNA synthesis, which may result in myopathy, 
peripheral neuropathy, pancreatitis, and lactic acidosis [22, 23].  
1.4.3 Non-nucleoside reverse transcriptase inhibitors 
 The NNRTI act by binding non-competitively to the RT enzyme. The binding 
causes conformational change in the three-dimensional structure of the enzyme [24]. First-
generation NNRTIs include nevirapine, delavirdine, and efavirenz. These drugs have low 
genetic barrier and poor resistance profile, which led to the development of the second-
generation of NNRTIs. The new generation includes etravirine and rilpivirine. 
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1.4.4 Integrase inhibitors 
 Integrase inhibitors act by interfering with insertion of viral genome into host cell 
genome by blocking the binding of the preintegration complex to cellular DNA. Clinically 
approved integrase inhibitors include dolutegravir, cabotegravir (CAB), elvitegravir, and 
raltegravir. Integrase inhibitor are generally well tolerated and are recommended as part 
of initial HIV therapy along with 2 NRTIs. 
1.4.5 Protease inhibitors 
 Protease inhibitors act by inhibiting cleavage of the viral gag and gag-pol protein 
precursors into functional proteins, blocking nascent virion maturation and its infectivity 
[25]. There are several approved protease inhibitors such as, atazanavir and darunavir, 
that are commonly used in combination with low-dose ritonavir as a booster due to its 
ability to inhibit CYP3A4 slowing down the metabolism of the protease inhibitors [26]. 
1.4.6 ART-associated challenges 
 Development of viral drug resistance was a major challenge during early use of 
ARTs. This was attributed to the high mutation rate of the viral genome during active 
replication, limiting the effectiveness of monotherapy. Therefore, combination ART (cART) 
was employed targeting multiple stages of the viral life-cycle. Effective treatment of HIV 
requires lifelong administration cART with near perfect adherence as patient non-
adherence is the main cause of treatment failure. Factors associated with patient non-
adherence include: 1) factors related to treatment regimens as more complex regimens 
are associated with decreased adherence; 2) social and emotional status of the patient 
and availability of health care provider support; 3) personal factors related to younger age, 
minority status, and frequent history of substance abuse [27]. Rapid viral rebound due to 
non-adherence has been attributed to HIV latency where current drugs are not effective 
due to slow viral replication. Additionally, this slow replication during latency can occur in 
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HIV cellular and/or anatomical reservoirs where current formulations do not have access 
[28, 29].  
Among cellular reservoirs, memory CD4+ T cells, including both transitional 
(CD45RA-CCR7-CD27+) and central (CD45RA-CCR7+CD27+) T cells, one of the 
sources of persistent latency. Naïve CD4+ T cells have also been reported as sites of HIV 
latency, although at much lower intensity than memory T cells. Recently, integrated HIV 
DNA has been detected in CD34+ hematopoietic progenitor cells from 40% of patients 
under cART [30]. Also, astrocytes isolated from HIV-infected patients showed the 
presence of integrated HIV DNA, which has been linked to HIV-associated dementia. 
However, this finding was in patients exhibiting active viremia, and further studies on 
patients under cART are required. Furthermore, monocyte-macrophages have been 
reported as HIV reservoirs. However, to lesser extent than CD4+ T cells that is attributed 
to lower CD4 expression on macrophages, and to restrictions in nuclear import and 
reverse transcription resulting in limited infection [30]. 
Several anatomical reservoirs have been reported with gastrointestinal tract being 
the most prominent reservoir with five- to ten-fold higher viral load than PBMCs. Infected 
CD4+ T cells carrying the viral genome through the lymphatic circulation renders lymphoid 
tissue an important reservoir. Moreover, follicular dendritic cells residing in the germinal 
center may provide a stable source of latent virus. HIV RNA has been detected in 
genitourinary tract of 54% of women and in semen of 8 to 10% of men on suppressive 
cART, indicating a reservoir in the genital tracts. Furthermore, the blood-testis barrier 
restricts the entry of immune cells, providing a niche for viral latency [31, 32]. 
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1.5 Long-acting antiretroviral therapy 
Long-acting (LA) formulations have proven to be very successful in diverse areas 
of medicine including, contraception [33], type 2 diabetes [34], psychotic diseases,  
neuroendocrine tumors [35] and many others. Furthermore, there are considerable efforts 
to generate LA antimalarial [36] and anti-tuberculous drugs [37]. In the case of second-
generation LA antipsychotics, several formulations are available in clinical practice that 
have shown to be superior to their oral counterparts. Interestingly, a 3-monthly injection 
formulation of paliperidone has been approved and it is a first LA injectable agent to extend 
the dosing regimen beyond the typical monthly regimen [38]. LA formulations have the 
advantage of improving patient adherence, reducing risk of overdose and accidental 
poisoning, and increasing drug bioavailability for those with difficulty absorbing oral 
medications. In contrast to daily regimens, LA formulations offer sustained plasma drug 
levels reducing the risk of drug level falling below its therapeutic window, which commonly 
occurs with missed doses; thus, reducing the risk of acquiring drug resistance (Figure 4). 
Additionally, LA drugs offer a means for differentiating between lack of efficacy and lack 
of adherence. incomplete adherence to anti-HIV therapy has been a concerning issue for 
both HIV treatment and prevention. To answer the question of willingness of patients to 
switch to LA drugs instead of once daily regimens, a survey was conducted where 74% of 
400 HIV infected patients reported that they would consider switching to LA ART [39]. 
However, adherence is even more concerning in healthy at high-risk population due to, 
beside not having the disease, their concern of being mistakenly recognized as HIV 
positive [40]. 
1.5.1 Challenges associated with LA ART 
 A critical challenge in developing LA ART, to be administered once monthly for 
example, is drug loading capacity. As an example, for the FTC studied in this project, the 
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drug is dosed orally at 200 mg once daily. To make a monthly injection, therefore, the drug 
delivery platform should be capable of encapsulating 6 g of FTC (a 30-day supply) in a 
reasonable injection volume. Therefore, the potency of the candidate drug along with the 
drug delivery system are critical for making LA ART clinically feasible. Most of the 
therapeutic agents in LA formulations are hydrophobic, posing an additional challenge 
compared to hydrophilic drugs, such as NRTIs and maraviroc [41]. In addition to the 
physical characteristics of the drug, changing the route of administration from oral to 
intramuscular (IM) or subcutaneous (SC) would affect drug absorption, distribution, and 
metabolism, all of which require thorough investigation and optimization. 
For LA injectables, the most commonly used formulations are oil-based formulations, such 
as some first-generation antipsychotics, haloperidol decanoate and fluphenazine 
decanoate [42]. These were composed of insoluble drugs dispersed in oils, such as 
sesame oil. However, this method is no longer in use due to the high excipient content 
required. To overcome the limitations of hydrophilic drugs, hydrophobic prodrug strategies 
have been employed, such as conjugating fatty acid chains to the parent drug or by making 
hydrophobic salts [43, 44]. As an alternative to oil-based formulations, drug suspensions, 
or nanosuspensions in particular, have received great attention because they offer higher 
drug loading capacity, higher biodistribution because of their ability to cross biological 
membranes such as the blood brain barrier, and due to their improved drug release 
profiles [45]. Interestingly, the 3-monthly injection mentioned earlier for an antipsychotic 
was formulated as an aqueous nanosuspension [46]. Taking into account the intrinsic 
properties of ART, the above-mentioned challenges render most ART drugs not suitable 
candidates for LA formulations. 
1.5.2 Cell-mediated drug delivery systems 
 Like CD4+ T cells, macrophages have excellent properties as an HIV reservoir. 
This is due to the long life span of the macrophage -- brain microglia can survive for years 
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-- and to the fact that macrophages are part of the immune system, which helps the virus 
evade the immune response. Therefore, targeting macrophages is a major challenge for 
eradicating HIV. In addition to targeting HIV residing in macrophages, one can utilize these 
cells as vehicles to deliver drugs to other tissues. This approach offers several advantages 
that include delivery to the site of infection or inflammation, particularly HIV anatomical 
reservoirs; prolongation of drug apparent half-life and controlled drug release, thus 
improving pharmacokinetics (PK); and minimization of drug immunogenicity. Furthermore, 
the ability of macrophages to cross biological barriers allows them to be used as “Trojan 
horses” to carry drugs, for example across the blood brain barrier [47].  
 Despite such advantages, there are several complications for efficient utilization of 
macrophages as delivery vehicles. These include: 1) loading a high amount of drug; 2) the 
need for the drug to be protected from intracellular lysosomal degradation; 3) a means to 
prevent premature release of the drug to ensure delivery at the desired site; 4) preventing 
the drug from affecting the transmigration abilities of the cells; and 5) ensuring that the 
drug  maintains its cellular biological functions during delivery [47]. To fulfill these 
requirements, our lab has developed cell-targeted long-acting slow effective release ART 
(LASER ART). Previous studies have shown that LASER ART is readily taken up by 
macrophages and  forms intracellular depots that can be safely delivered to viral reservoir 
sites, thus, prolonging drug half-life and improving drug biodistribution and efficacy [48-
52].  
1.6 Significance of the current project 
 FTC is an ARV drug used for treatment and prevention of HIV. The drug is a 
cytidine analogue that must be transformed by the host cell into its active metabolite, FTC 
triphosphate. It then acts by competing with native nucleoside triphosphates for integration 
into elongating viral DNA and leads to termination of viral reverse transcription. This drug 
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was selected for the current project based on its potency, bioavailability, and limited 
toxicity profile [53]. Furthermore, FTC in combination with tenofovir disoproxil fumarate 
(TDF), Truvada®, has proven effective as an oral once-daily pre-exposure prophylaxis 
measure (PrEP) [54]. Thus, creation of an LA FTC formulation should aid in better 
prevention of HIV because of the  non-adherence issues that exist with current PrEP [55]. 
Therefore, this important drug is an important candidate for conversion to an LA 
formulation with improved clinical properties. 
 This study was conducted in four phases. The first was to screen multiple 
poloxamers for optimization of nanoformulation strategy. The second was synthesizing a 
hydrophobic prodrug of FTC and its encasement in polymer nanoparticles along with 
extensive characterization of both the prodrug and the nanoparticle. The third was 
evaluation of the PK properties of the nanoparticle. The fourth phase investigated the 
antiretroviral efficacy of the nanoparticle in an in vivo animal model. 
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Figure 1.1 HIV-1 life-cycle. The infection begins with interaction of HIV envelope proteins 
and host cell surface receptors and co-receptors that leads to fusion of viral and cellular 
membranes. Viral reverse transcription takes place in the cytoplasm before trafficking of 
the viral capsid into the nucleus where the viral genome integrates into the host cell 
genome. 
The figure was modified from [56] 
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Figure 1.2 HIV pathogenesis. Once HIV is in the body, dendric cells (orange) carry the 
virus to CD4+ T cells that migrate to lymphoid tissues. The established infection, due to 
massive viremia, spreads throughout lymphoid tissues. An immune response specific to 
HIV occurs and traps the virus in the germinal centers of the lymphoid tissue. At this point, 
despite the immunological response, a chronic, persistent infection is established. Immune 
activation mediated by cytokines accelerates virus replication which, in association with 
rapid CD4+ T cell turnover, gradually destroys the host immune system. 
The figure was modified from [57]. 
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Figure 1.3 Chemical structures of ART. This figure shows examples of different 
classes of antiretroviral drugs along with their chemical structures.  
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Figure 1.4 Effect of dose fluctuation. Subtherapeutic concentration with an increased 
risk of acquiring drug resistance is represented by the dashed line. In contrast, LA injection 
maintains steady therapeutic drug concentrations. 
The figure is modified from [41]. 
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Chapter II. Poloxamer Screening for 
Enhanced Stability and Uptake of 
Nanoformulations 
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2.1 Abstract 
 While the need for LA ART is inevitable, targeting HIV cellular and anatomical 
sanctuaries by drugs able to penetrate into these sites has not yet been realized. Passive 
macrophage targeting by LA ART could provide a means to optimize a system for drug 
delivery to viral sanctuaries. However, a challenge to translate such ART rests in 
optimizing synthesis and formulation with production reproducibility. To this end, our lab 
has developed a simple, reproducible, and scalable synthesis process for nanoformulated 
LA ART for passive macrophage targeting. We have demonstrated that this can be 
achieved by encasing the drug with a polymeric stabilizer, poloxamer 407, that results in 
stable nanoparticles with high loading capacity. We now further optimize this process 
aiming for even more stable nanoparticles exhibiting higher uptake by monocyte-derived 
macrophages. We synthesized and characterized nanoparticles with multiple different 
poloxamers. The protease inhibitor atazanavir (ATV) was used without any modification, 
due to its intrinsic hydrophobic property that is essential for making nanoparticles with our 
method. The manufacturing scheme developed is superior to previously described 
methods based on greater simplicity and reproducibility of the process. Direct 
manufacturing provides a path toward large-scale production of macrophage-targeted LA 
ART.  
2.2 Introduction 
 LA ART has generated great interest in the pharmaceutical industry for the 
treatment and prevention of HIV infection. LA ART parenteral injections have 
demonstrated maintenance of plasma drug levels for months, overcoming the patient 
adherence issue associated with disease management [58]. Combination of LA CAB and 
rilpivirine (RPV) was the first regimen that demonstrated efficacy and safety comparable 
to the daily oral three-drug regimen [59]. Both CAB and RPV are highly potent drugs with 
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low aqueous solubility, allowing them to be formulated as suspensions by wet-milling [60, 
61]. However, the high injection volumes required, and injection site reactions were major 
limitations of this formulation, leading to patients withdrawing from clinical trials. 
Additionally, the inability of this formulation to penetrate into viral reservoirs limited its 
therapeutic outcomes [59, 62, 63]. To avoid these limitations, we investigated different 
poloxamers as surfactants, first to ensure a longer stability nanoformulation in different 
storage conditions, and second, to enhance drug uptake by monocyte-derived 
macrophages (MDMs), one of the viral reservoirs and perhaps for delivery to other tissues.  
 Poloxamers, with the trade name Pluronic® (BASF, NJ, USA), are a family of more 
than 50 different amphiphilic nonionic block copolymers consisting of a central 
hydrophobic propylene oxide (PO) chain and two hydrophilic ethylene oxide (EO) polymer 
chains flanking both sides of the PO polymer. All poloxamers have similar structures, 
where PO and EO are arranged in EOa-POb-EOa structures and their hydrophilic-lipophilic 
balance is determined by the number of EO and PO moieties. Since their introduction, 
they have been used in a wide range of applications in the pharmaceutical and other 
biomedical industries as emulsifying, solubilizing, or dispersing agents and as in vivo 
absorbance enhancers [64]. Interestingly, poloxamers have been shown to promote drug 
penetration through the blood-brain barrier by inhibiting drug efflux transporters, 
suggesting that they would enhance drug biodistribution and allow targeting of viral 
reservoirs in the central nervous system [65]. Table 1 presents a list of select poloxamers 
and their respective properties. These poloxamers represent the best match to our needs 
as they can encase hydrophobic drugs by their PO hydrophobic central polymer chain 
while their EO hydrophilic polymer chains facilitate formation of an aqueous suspension. 
 Nanocrystals dispersed in aqueous suspension have demonstrated improvement 
in the clinical efficiency of drugs by 1) enhancing bioavailability; 2) lowering of dose 
requirement; and 3) facilitating sustained release of drugs. Having nanocrystals in 
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aqueous suspension has its own advantages: 1) drugs remain in the required crystalline 
state with reduced particle size, leading to increased dissolution rate, thus improved 
bioavailability; 2) drugs no longer need to be in soluble form, especially valuable for 
molecules insoluble in oils; 3) high drug loading can be achieved becaue drugs exist in 
the form of pure solid which can reduce the administration volume for high doses; and 4) 
nanosuspensions can increase the physical and chemical stability of drugs because they 
are in a solid state [66]. 
 To prepare suspensions of nanosized crystals (nanosuspension), a high-pressure 
homogenization method was used. Advantages offered by this method are 1) even 
dispersion of ingredients within the  medium; 2) good reproducibility; 3) an organic solvent-
free method; 4) large-scale production capability by pharmaceutical industry because 
these homogenizers are available with different capacities ranging from hundreds to 
thousands of liters per day [67]. The formation of nanosuspensions with this method is 
based on the cavitation forces created in high-pressure homogenizers (Figure 2.1). After 
high-pressure homogenization, excessive poloxamer is removed by differential 
centrifugation to minimize the amount of excipient. However, this centrifugation process 
may result in particle aggregation during resuspension and limit large-scale manufacture. 
 Here we describe a simplified, scalable, and reproducible method for generating 
macrophage-targeted nanoparticles to abrogate purification process. The resultant 
nanoparticles demonstrated prolonged particle stability with good potential for large-scale 
manufacture.  
 Mean particle size, polydispersity index (PDI), and zeta-potential are important 
characteristic parameters to determine particle stability, dissolution rate, and in vivo 
behavior of nanosuspensions. Based on prior experience (Refs), particle size of 350 – 500 
nm are most likely to form a stable formulation. The PDI is also an important parameter 
that governs the physical stability of nanosuspensions and should be as low as possible 
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for long-term stability of nanosuspensions. A PDI value of 0.1 – 0.3 indicates a fairly 
narrow size distribution, whereas PDI values greater than 0.5 indicate a very broad 
distribution [68]. Zeta-potential provides information about the surface charge of the 
particle and an impression about its long-term stability. The zeta-potential of a 
nanosuspension is governed by the stabilizer and the drug itself. For a nanosuspension 
stabilized by electrostatic repulsion, a minimum zeta-potential of ± 30 mV is required, 
whereas for a combined electrostatic and steric stabilizer, a zeta-potential of ± 20 mV 
would be sufficient [69].  
2.3 Materials and Methods 
2.3.1 Materials 
 ATV was purchased from Longshem Co. (Shanghai, China) and free-based with 
triethylamine. Poloxamers 407, 403, 338, 238, 237, and 188 were purchased from BASF 
(Florham Park, NJ). Dulbecco’s Modified Eagle’s Medium (DMEM) was purchased from 
Corning Life Sciences (Tewksbury, MA). Heat-inactivated pooled human serum was 
obtained from Innovative Biologics (Herndon, VA). Gentamicin, high performance liquid 
chromatograph (HPLC) grade acetonitrile (ACN), HPLC grade methanol, and Optima 
grade water were purchased from ThermoFisher Scientific (Waltham, MA, USA). 
2.3.2 High-pressure homogenization 
 For preparation of nanosuspensions, 1% (w/v) ATV was added to a solution of 
0.5% (w/v) poloxamer in 10 mM HEPES buffer, pH 7.8 (Figure 2.2). For optimized direct 
preparation, 1% (w/v) ATV was added to either 0.06% or 0.1% (w/v) poloxamer in 10 mM 
HEPES buffer, pH 7.8 (ATV to polymer ratio was 2:1). The premix was stirred with 
magnetic bar for 16 hours at room temperature followed by homogenization using high-
pressure homogenizer (Avestin EmulsiFlex-C3; Avestin Inc., Ottawa, ON, Canada) at 
20,000 psi until a desired particle size of 300-400 nm was attained. 
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2.3.3 Formulation purification by differential centrifugation  
Crude nanosuspensions were purified by a series of centrifugations. The 
homogenized suspension was first centrifuged at 10,000 × g for 15 min. The supernatant 
was discarded, and the pellet was re-suspended in 0.2% (w/v) poloxamer solution. The 
re-dispersed nanoparticles were centrifuged at 200 × g for 1 min to remove large particles 
that were poorly dispersed. Supernatant from the secondary centrifugation was collected 
as the final formulation. 
2.3.4 Nanoparticle physicochemical characterization 
 Nanoparticle diameter, PDI, and zeta-potential were measured by dynamic light 
scattering (DLS) using a Malvern Zetasizer, Nano Series Nano-ZS (Malvern Instruments, 
Inc, MA, USA). All measurements were performed with samples stored at 25 °C without 
stirring. Encapsulation efficiency for the formulation was calculated by the following 
equation:  
Encapsulation efficiency (%) = 
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑖𝑛 𝑓𝑜𝑟𝑚𝑢𝑙𝑎𝑡𝑖𝑜𝑛
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑎𝑑𝑑𝑒𝑑
 X 100 
2.3.5 Nanoparticle monocyte-derived macrophage uptake 
 Human peripheral blood monocytes were obtained and cultured as described 
previously [70]. Briefly, peripheral blood monocytes were obtained by leukapheresis from 
HIV-1/2 and hepatitis B seronegative donors, followed by purification by countercurrent 
centrifugal elutriation. Monocytes were cultured in DMEM supplemented with 10% heat-
inactivated pooled human serum, 10 μg/mL ciprofloxacin, 50 μg/mL gentamicin, and 1,000 
U/mL recombinant macrophage colony stimulating factor to drive monocyte-macrophage 
differentiation. Monocytes were allowed to differentiate to macrophages for 7-10 days. 
Then cells were treated with 100 μM ATV nanoformulations. At predetermined time points, 
MDMs were washed three times with sterile phosphate-buffered saline (PBS) and scraped 
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into 1 mL PBS. Cell pellets were collected by centrifugation at 2,000 × g for 8 min, followed 
by probe sonication in 200 μL HPLC grade methanol to extract ATV.  
2.3.6 ATV quantitation 
 ATV concentration was measured by HPLC. We assessed the samples by reverse 
phase HPLC using triplicate 10 µL injections onto a YMC Octyl C8 column (Waters Inc, 
Milford, MA). Mobile phase consisting of 48% ACN / 52% 25 mM KH2PO4, pH 4.15 at flow 
rate of 0.4 mL/min with UV/Vis detection at 272 nm. Quantification was determined by 
comparison of peak areas to a standard curve of ATV (0.05-50 µg/mL) in methanol. 
2.4 Results 
2.4.1 ATV nanoformulation (NATV) synthesis with purification 
 NATV was prepared by premixing ATV with different poloxamers illustrated in 
Table 2.1 (P407, 403, 338, 238, 237, or 188) with drug to polymer weight-to-weight ratio 
2:1. After overnight mixing, the premixes were processed by high-pressure 
homogenization to reduce the particle size. The size and PDI of the nanoparticles 
produced with different poloxamers were comparable as follows 350-450 nm and 0.25-
0.3, respectively. However, the zeta-potential was variable ranging from -5 to -20 mV. 
Nevertheless, after differential centrifugation, approximately 30% of the drug was lost and 
encapsulation efficiency reduced to 70% during this process. Additionally, only 3 
formulations retained particle sizes of 400-500 nm (ATV-P407, ATV-P403, and ATV-P338) 
whereas all other formulations were aggregated, reaching particle sizes of several 
microns. Of those that maintained the desired particle size, only ATV-P403 remained 
within the acceptable range while the others all aggregated by day 7 (Figure 2.3A). These 
results were concomitant with PDI measurements (Figure 2.3B). Surprisingly, zeta-
potential of the three nanoformulations did not change until day 7 (Figure 2.3C). 
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2.4.2 ATV nanoformulation by direct manufacture 
 To preclude particle aggregation caused by harsh pressure during differential 
centrifugation, we determined the polymer content required to develop a simplified direct 
manufacture method to avoid centrifugation (Figure 2.4). To achieve this, the drug to 
polymer ratios were determined by evaluation of integral areas in the proton nuclear 
magnetic resonance (1H-NMR) spectra as described previously [71]. To optimize 
manufacture conditions, two drug-to-polymer ratios were tested, 100:10 and 100:6. NATV 
prepared by direct manufacture at either drug-to-polymer ratio exhibited high drug loading 
without compromising particle integrity. High-pressure homogenization achieved stable 
nanoparticles in terms of particle size and PDI with all tested poloxamers for at least 8 
weeks except for ATV-P338 100:6 and ATV-P188 100:6 that did not remain stable beyond 
3 and 1 week, respectively (Figure 2.5A and B). However; the zeta-potential of all 
formulations remained within the acceptable range for 8 weeks (Figure 2.5C). 
2.4.3 NATV uptake and retention in MDMs 
 The elimination of the purification step after homogenization significantly enhanced 
particle stability and increased encapsulation efficiency to more than 90%. Therefore, 
nanoformulation prepared by direct manufacture was moved to MDM uptake and retention 
studies. Since ATV made stable nanoparticles with all tested poloxamers at a 100:10 drug-
to-polymer ratio, these formulations were tested for MDM uptake and retention. Treatment 
of MDMs to NATV showed increasing drug uptake for the course of 8 hours. Although 
ATV-P407 and -P188 exhibited the highest uptakes, there were no significant differences 
in uptake among all tested poloxamers (Figure 2.6A). After 8-hour exposure of MDMs to 
NATV, the drug was retained intracellularly for at least 15 days, with no significant 
differences among the tested poloxamers (Figure 2.6B). 
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2.5 Discussion 
 LA ARVs show promise providing prolonged dosing intervals and less fluctuation 
in plasma drug levels, presumably improving therapeutic outcomes for HIV/AIDS. LA 
ARVs have potential to improve regimen adherence, reduce systemic toxicities antiviral 
mutations, and reduce the stigma related to daily regimens of ART [58, 72]. A successful 
regimen requires high drug encapsulation that would maintain a sufficient amount of drug 
for months and with a readily injectable volume. In addition, loaded drugs toned to be 
released in a pattern that is sufficient to provide therapeutic drug levels, yet slow enough 
to avoid high concentrations with their related toxicities and to achieve prolonged dosing 
intervals. 
 Nanocrystals provide an improved strategy to formulate hydrophobic LA ART. 
They offer high drug loading capacity while eliminating organic solvent usage, therefore 
reducing relevant toxicities. After injection of the nanocrystals, the injection site serves as 
a primary depot from which drug is dissolved and eventually released into the circulation. 
Sustainable release for weeks to months can be achieved with drugs that have low 
aqueous solubility. RPV and CAB LA formulations are both nanocrystals with 
approximately 200 nm diameters manufactured by wet-milling, a commonly used top-
down method to prepare nanoparticles. The presence of surfactants such as polysorbates 
and poloxamers is essential to prevent particle aggregation. High-pressure 
homogenization is another size reduction technique that reduces particle size by forcing 
of a suspension under pressure through a valve with a narrow aperture [73]. This method 
presumably precludes formulation contamination from the worn beads that are used in 
wet-milling. 
 Poloxamers are widely used surfactants in the pharmaceutical industry because 
of their unique characteristics. Having both hydrophilic and lipophilic polymer chains, they 
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have been used to formulate poorly water-soluble drugs, in addition to their capabilities to 
make LA suspensions. Although each poloxamer has unique physiochemical 
characteristics, particularly hydrophilic-lipophilic balance, all tested poloxamers resulted 
in stable formulations after direct manufacture, except for ATV-P338 and -P188 with a 
100:6 drug-to-polymer ratio. Failure of these formulations can likely be attributed to a low 
amount of poloxamer that was presumably insufficient to fully encase the drug. 
 Macrophages and CD4+ T cells are primary cellular reservoirs for HIV-1 [30]. Our 
next goal is to employ macrophages as “Trojan horses” to deliver nanoparticle drugs to 
another cellular target. Macrophages are highly mobile cells and readily cross biological 
barriers to sites of inflammation and infection. Drug crystals in the endosomal 
compartments of macrophages could therefore cross physiological barriers to reach viral 
reservoirs such as the gut, brain, and lymph node [31]. Depending on surface chemistry 
and lipophilic properties, nanoparticles phagocytosed by macrophages can be released 
into the blood stream and surrounding tissues. This secondary depot should further reduce 
maximal plasma drug concentration (Cmax) and prolong apparent half-life (t1/2), which 
could potentially reduce overall dosage as well as drug-induced toxicities. 
seems out of place here 
2.6 Conclusions 
 Though current LA ART nanoformulations demonstrate real potential for improving 
HIV management and prevention, further refinements in medicinal and polymer chemistry, 
for example increasing lipophilicity of the drug, could produce a more optimal drug delivery 
system and further improve viral restriction [50, 74].This study focused on overcoming the 
technical hurdles that are commonly faced during nanoformulation preparation. The direct 
manufacture procedure used here is highly reproducible and scalable and could be 
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applied to other similar formulation platforms, which represents an important step forward 
in development and translation of next generation LA ART. 
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2.7 Figures and tables 
 
Table 2.1 Poloxamer characteristics. The table shows select poloxamers and their 
composition along with their hydrophilic-lipophilic balance (HLB). A higher y value renders 
the poloxamer more lipophilic whereas higher x or z values makes it more hydrophilic. 
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Figure 2.1 High-pressure homogenization. The pre-suspension passes through a very 
small homogenization gap in the homogenizer, typically having a width of 25 µm at 1500 
bar. Due to the narrowness of the gap, the streaming velocity of the suspension and the 
dynamic fluid pressure increases. In addition, the static pressure on the fluid decreases 
below the boiling point of water at room temperature. Consequently, water starts boiling 
at room temperature and gas bubbles are formed that implode (cavitation) when the fluid 
leaves the homogenization gap. These cavitation forces are strong enough to break the 
drug microcrystals into nanocrystals. 
The figure was modified from [73]. 
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Figure 2.2 Particle size reduction scheme. ATV was dispersed with the poloxamer 
followed by high-pressure homogenization until the desired particle size and PDI were 
achieved. The resultant nanosuspension contains excessive polymer that requires 
purification. 
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Figure 2.3 NATV stability after purification. Only 3 nanoformulations had stable particle 
size (A)and PDI (B) for 3 days after the purification step; ATV-P407 and -P338 aggregated 
by day 7. The zeta-potential (C) did not change during the course of the study with any of 
the nanoformulations. 
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Figure 2.4 NATV Direct manufacture. Direct manufacture process where drug to 
polymer ratio was optimized to preclude the need for removal of excessive polymer by 
centrifugation.  
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Figure 2.5 NATV stability after direct manufacture. Avoiding centrifugation after 
homogenization resulted in stable nanoparticles in terms of (A) particle size and (B) PDI 
for 8 weeks except for ATV-P338 and -P188 at 100:6 drug-to-polymer ratio. (C) the zeta-
potential remained within an acceptable range for 8 weeks. 
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Figure 2.6 NATV uptake and retention in MDMs. (A) Exposure of MDMs to NATV 
resulted in steady increasing uptake. (B) After 8-hour exposure, the drug was retained in 
MDMs for at least 15 days. No significant differences were found among all tested 
poloxamers.  
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Chapter III. Synthesis and 
Characterization of a Long-Acting 
Emtricitabine Prodrug Formulation 
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3.1 Abstract 
Aims: A palmitoylated prodrug of FTC was synthesized then encased into a LA 
nanoformulation extending the native drug’s apparent half-life, antiretroviral activities, and 
biodistribution to tissue viral reservoirs. 
Methods: A chemically modified FTC prodrug (MFTC) was synthesized by esterification 
with palmitoyl chloride. MFTC’s structure and crystallinity were confirmed by 1H- and 13C-
NMR, Fourier transform infrared spectroscopy and X-ray diffraction. A P407 coated 
aqueous nanosuspension of MFTC (NMFTC) was prepared by high-pressure 
homogenization. NMFTC uptake, retention and antiretroviral efficacy were examined in 
human MDMs. Drug PK and tissue distribution were evaluated in Sprague-Dawley rats 
after a single IM injection of 45, 75, or 100 mg/kg FTC-equivalents. FTC and its active 
triphosphate metabolite (FTC-TP) were quantified by liquid chromatography tandem mass 
spectrometry. 
Results: FTC was conjugated to the long chain fatty acid palmitoyl chloride. The 
hydrophobic prodrug coated with P407 formed stable water insoluble nanocrystals. 
NMFTC exhibited particle sizes of 350 ± 30 nm, PDI of 0.24 ± 0.02, zeta potential of -20 ± 
2 mV, and encapsulation efficiency of 85%.  MFTC nanoparticles were readily taken up 
by MDMs with high intracellular FTC-TP and extended PK profiles. 
Conclusion: LA NMFTC showed physicochemical stability, improved antiretroviral 
efficacy and extended plasma half-life compared to its native drug. This work represents 
a step forward in the development of LA FTC drug therapies.  
3.2 Introduction 
UNAIDS has recently highlighted the significant toll seen by HIV infections 
worldwide [12]. In 2017, approximately 37 million people worldwide were infected. Of 
those, 1.8 million were children under the age of 15. Despite global efforts to treat and 
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prevent viral infection, about 1 million people have died of the infection. Equally concerning 
is that only 21.7 million infected people had access to ART. It is estimated that $26.2 billion 
will be required to control and prevent HIV infection in the developing world by 2020.  
To reduce the spread of HIV infection, improved access to ART and continuous 
adherence to therapeutic regimens are needed. Effective treatment of infection requires 
early, daily, and lifelong therapy [75]. While currently available therapeutic regimens have 
demonstrated remarkable success in reducing disease morbidity and mortality, treatment 
failures abound. These are due, in part, to patient non-adherence to complex drug 
regimens and to the stigma of infection itself [76, 77]. Nonetheless, cART regimens are 
required to ensure reductions in viral load, maintenance of CD4+ T cell counts, prevention 
for the emergence of drug resistant viral strains, and in eliminating viral transmission [78]. 
The inability of current antiretroviral drugs (ARVs) to target viral reservoirs (including the 
lymph nodes, gut, central nervous system, genitourinary system and spleen) has also 
reduced therapeutic success  [79].  
To address each and more of these limitations, LA ARV regimens were developed. 
They serve to improve patient adherence, decrease drug toxicities, and maintain viral 
suppression while also diminishing the stigma of ARV use. LA ART are made by encasing 
ARVs into poloxamer coated nanocrystals that facilitate intracellular drug depots at the 
injection site and within macrophages of the reticuloendothelial system and other tissue 
viral compartmentalization sites [80]. At present, LA ART are highly protein bound, 
metabolized and released slowly, and housed in depots where drug is released in time 
measured from days to weeks. Research in our own laboratories have extended this drug 
platform by the use of MDMs as cell-based drug depots and as vehicles for drug delivery 
to viral reservoir tissue sites [81]. Each of these serve to improve ARV PK and 
pharmacodynamics (PD) profiles [82].  
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Despite active research into LA ARVs only two antiretrovirals, CAB and RPV are 
now being developed for human use as LA medicines [59]. Thus, there is an imperative 
for further research and drug development in this area. This is especially important for LA 
transformation of the NRTIs as they represent the backbone of current ART regimens. 
Indeed, the standard of care once a day antiretrovirals are administered as two NRTIs and 
an integrase or NNRTI [83]. Amongst these, the most potent and widely used NRTIs for 
treatment of infection are FTC, TDF and 3TC [84-86]. Truvada®, a once daily regimen of 
FTC and TDF,  combination has also shown to be effective in PrEP [54]. Thus, expanding 
available LA formulations for each or all of these medicines would have a significant impact 
on the care, treatment and prevention of HIV/AIDS.  
In efforts to achieve a once-a-month or even longer dosing frequencies, our 
laboratory has recently created LA NRTI prodrug formulations [48, 51]. While a dream a 
few years ago, creating a LA ARV library is now within reach [49, 51, 52, 87, 88]. Notably 
and in the present report, FTC was chemically modified to create a LA agent. FTC was 
chosen based on its bioavailability and limited toxicity profiles [53]. FTC is a potent cytidine 
analogue that is transformed into its active triphosphate metabolite in cells where it 
competes with endogenous cytidine triphosphates for incorporation into the viral DNA 
chain during viral reverse transcription [89]. A major obstacle in transforming FTC into a 
LA agents rested in its hydrophilicity. With this in mind we created a first-generation 
hydrophobic FTC prodrug amenable to nanoparticle encasements. This was done by 
conjugating it to a long chain palmitoyl fatty acid. The hydrophobic nanocrystal prodrugs 
were stabilized into an aqueous solution by P407. The nanosuspension offered increased 
dissolution rates and long term profiles as drugs remain in nanocrystals with high 
encapsulation efficiency, and physicochemical stability [45]. The developed nanoparticles 
are readily taken up by MDMs and reside inside subcellular endosomes for prolonged time 
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period with stable FTC-TP conversion levels. PK profile assessed in rats was significantly 
improved over the native drug. As such, this nanoformulated FTC prodrug could be 
employed as a first step in formulation development with the aim of improving patient 
adherence, reducing adverse reactions and targeting drug to HIV infectious reservoirs.  
3.3 Materials and methods 
3.3.1 Materials 
FTC was purchased from HBCChem (Union City, CA). Palmitoyl chloride, 
tetrahydrofuran (THF), tert-butylmagnesium chloride (tBuMgCl), 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) buffer, ciprofloxacin, dimethyl sulfoxide (DMSO), 
paraformaldehyde (PFA), ammonium acetate, 3,3`-diaminobenzidine (DAB), type XA acid 
phosphatase (EC 3.1.3.2) from sweet potatoes, Histopaque-1083, and Hank’s Balanced 
salt solution (HBSS) were purchased from Sigma Aldrich (St. Louis, MO). Poloxamers 
407, 403, 338, 238, 237, and 188 were purchased from BASF (Florham Park, NJ). Thin-
layer chromatography was performed on precoated F-254 silica plates (250 µm) from 
SiliCycle, Inc. (Quebec City, QC, Canada). LC-MS grade water, PBS, diethyl ether, 
gentamycin, ACN, methanol, Triton X-100, and dichloromethane (DCM), acetic acid, and 
ammonium hydroxide were purchased from Fisher Scientific (Waltham, MA). DMEM was 
purchased from Corning Life Sciences (Tewksbury, MA). Monoclonal mouse anti-human 
HIV-1 p24 (clone Kal-1), monoclonal mouse anti-human leukocyte antigen (HLA-
DP/DQ/DR; clone CR3/43), and the polymer-based HRP-conjugated anti-mouse 
EnVision+ secondary antibody were purchased from Dako (Carpinteria, CA). cell counting 
kit-8 (CCK-8) was purchased from Dojindo Molecular Technologies, Inc. (Rockville, MD). 
FTC-TP was purchased from Toronto Research Chemicals (North York, Canada). Sep-
Pak QMA anion-exchange cartridges and OASIS HLB reverse-phase cartridges were 
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purchased from Waters Corp. (Milford, MA). Potassium chloride (KCl) was purchased from 
JT Bakers Co. (Phillipsburg, NJ). 
3.3.2 MFTC synthesis and characterization 
FTC (2.0 g, 8.089 mmol, 1 equivalent) was dried by azeotroping from anhydrous 
pyridine (15 mL), resuspended in anhydrous THF (30 mL), cooled to -78°C, followed by 
addition of tBuMgCl (8.089 mmol, 1 equivalent, 1 M in THF) and allowed to stir for 15 
minutes under an argon atmosphere. A solution of palmitoyl chloride (2.26 g, 8.089 mmol, 
1 equivalent) was then added dropwise to the FTC anion at -78°C. The reaction mixture 
was gradually warmed to room temperature and stirred for 16h, quenched using saturated 
ammonium chloride solution, concentrated, and subjected to flush chromatography 
purification to isolate MFTC as a colorless powder. Proton (1H)- and carbon (13C)- NMR 
spectra were recorded on a Varian Unity/Inova-500 NB (500 MHz; Varian Medical 
Systems Inc., Palo Alto, CA). FTIR was performed on a PerkinElmer universal attenuated 
total reflectance (UATR) Spectrum Two (Waltham, MA). The aqueous solubility of FTC 
and MFTC were determined by adding excess drug to water followed by mixing for 24 h 
at room temperature. Samples were centrifuged at 14,000 rpm for 10 min to remove 
undissolved drug. Solubilized drug in the supernatant was quantified using a Waters 
ACQUITY ultra-performance liquid chromatography (UPLC) with TUV detector and 
Empower 3 software (Milford, MA). FTC and MFTC drug extracts were separated on a 
Phenomenex Kinetex 5 µm C18 column 100A (Torrance, CA) using either 95% 20 mM 
ammonium acetate buffer in 5% ACN, pH 3.9, or 90% methanol/10% water with a flow 
rate of 1.0 mL/min and detected at 272 and 280 nm, respectively. Drug content was 
quantified by comparison of peak areas of known standards (0.05-50 µg/mL).  
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3.3.3 Nanoformulation preparation and characterization 
For preparation of NMFTC nanosuspension, a pre-suspension of 1% (w/v) MFTC 
and 0.5% (w/v) P407 in 10 mM HEPES buffer (pH 5.5) was made and nanosized by high-
pressure homogenization (Avastin EmulsiFlexC3; Avastin Inc., ON, Canada) at 20,000 psi 
until the desired particle size of 300-400 nm was achieved. Particle size, PDI, and zeta-
potential were assessed by DLS using a Malvern Zetasizer Nano Series Nano-ZS 
(Westborough, MA). The stability of NMFTC was monitored at room temperature and 4 °C 
for up to 10 weeks in terms of particle size, PDI, and zeta-potential. The crystalline 
structures of MFTC was determined by X-ray diffraction (XRD) that was performed in the 
2θ range of 2–40° using a PANalytical Empyrean diffractometer (Westborough, MA) with 
Cu-Kα radiation (1.5418 Å) at 40 kV and 45 mA setting. A mask of 20 mm and a divergence 
slit of 1/8° were used on the incident beam path. The diffraction data was collected in steps 
of 0.04 degrees by continuously scanning at the rate of 0.013 °/s. 
3.3.4 Nanoparticle macrophage uptake, retention, and cytotoxicity 
Human peripheral blood monocytes were obtained from HIV- and hepatitis-
seronegative donors and purified by centrifugal elutriation at the University of Nebraska 
Medical Center (UNMC) elutriation core facility. The monocytes were cultured on 12-well 
plates at a density of 1 million cells per well and allowed to differentiate into macrophages 
in DMEM culture media consisting of 10% human serum, 1% glutamine, 50 μg/mL 
gentamicin, 10 μg/mL ciprofloxacin, and 1000 U/mL macrophage colony-stimulating factor 
for 7–10 days. Cell uptake was assessed at various time points after incubation with 100 
µM NMFTC. At each time point, adherent MDMs were washed three times with 1 mL PBS, 
scraped into 1 mL PBS, and pelleted by centrifugation at 8,000 rpm for 8 minutes at 4 °C. 
The cell pellet was reconstituted in 200 µl of methanol and probe-sonicated at 15% 
amplitude (QSonica Q55; Qsonica, LLC, CT, USA), followed by centrifugation at 14,000 
rpm for 10 minutes at 4 °C to pellet cell debris. FTC or MFTC concentration in the 
41 
 
 
 
supernatant fluid was quantified by UPLC as described above. To determine the extent 
and duration of retention, cells were incubated with 100 µM NMFTC for 8 hours and then 
washed with PBS to replace the medium with fresh drug-free medium. At various time 
points, cells were washed with PBS, collected, and analyzed for drug concentrations as 
described for the uptake study. For cellular cytotoxicity assay, monocytes were cultured 
on a 96-well plate at a density of 8,000 cells per well and allowed to differentiate into 
macrophages as described above. MDMs were exposed to various concentrations of the 
drug ranging from 0.05 – 500 µM. After 24 h, 10 µL of CCK-8 solution was added to each 
well, followed by 2 h incubation prior to absorbance measurement at 450 nm wavelength 
on a Molecular Devices SpectraMax M3 plate reader with SoftMax Pro 6.2 software 
(Sunnyvale, CA). 
3.3.5 NMFTC antiretroviral activities 
Antiretroviral efficacy was determined by measuring HIV RT activity. For half 
maximum effective concentration (EC50) determination, MDMs were exposed to various 
concentrations (0.01-1000 nM) of MFTC for 1 h followed by challenge with HIV-1ADA, a 
monocyte-tropic variant of HIV-1, at a multiplicity of infection (MOI) of 0.1 infectious 
particles per cell for 4 h. After viral challenge, cells were washed and incubated with the 
same concentration of drug used before infection for an additional 10 days. Culture fluids 
were collected on day 10 for measurement of RT activity as previously described [90, 91]. 
To evaluate the antiretroviral efficacy, MDMs were exposed to 100 μM NMFTC for 8 hours. 
The cells were then washed with PBS to remove any remaining nanoparticles not taken 
up by the cells. At various time points, the MDMs were then challenged with HIV-1ADA, at 
a MOI of 0.1 infectious viral particles per cell for 18 hours. Ten days after each challenge, 
viral activity was determined by measuring RT activity in the culture medium as previously 
described [90, 91]. HIV-1 p24 antigen expression was assessed on adherent cells as 
follows. After collecting the medium for RT assay, cells were washed with PBS and then 
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fixed with 4% PFA for 15 min at 37 ºC. Non-specific antibody binding on the cell surface 
was blocked using 10% bovine serum albumin containing 1% Triton X-100 in PBS for 30 
min at room temperature. Following blocking, cells were incubated with HIV-1 p24 mouse 
monoclonal antibodies overnight at 4 °C, followed by 1-hour incubation at room 
temperature. HRP-conjugated polymeric anti-mouse secondary antibody was added as 
one drop per well. Hematoxylin was added to counterstain the nuclei and images were 
visualized from a Nikon TE300 microscope with a 20X objective. 
3.3.6 Particle morphology: transmission electron microscopy (TEM) 
TEM was used to visualize the morphology of the nanoparticles, and to visualize 
nanoparticles taken up by macrophages. For nanoparticle morphology, the 
nanosuspension was dried on a copper grid at room temperature and bright field images 
were taken with exposure times of 2 s. Macrophages loaded with nanoparticles were 
analyzed after NMFTC exposure for 4 h. Cells were collected in PBS, centrifuged at 3000 
rpm for 8 min at room temperature. The cell pellet was fixed in a solution consisting of 2% 
glutaraldehyde, 2% PFA in 0.1 M Sorenson’s phosphate buffer (pH 6.2). During 
processing, samples were post-fixed in a 1% aqueous solution of osmium tetroxide for 30 
minutes. Subsequently, samples were dehydrated in a graded ethanol and propylene 
oxide used as a transition solvent between the ethanol and araldite resin. Samples were 
allowed to sit overnight in a 50:50 propylene oxide:resin solution until all the propylene 
oxide had evaporated then they were incubated in fresh resin for 2 h at room temperature 
before embedding. Polymerization took place at 65°C for 24 h. The staining procedure 
was 10 minutes in 2% (w/v) uranyl acetate, washed 3 times in distilled water, 10 minutes 
in Reynolds Lead Citrate, and washed 3 times in distilled water. Thin sections (100 nm) 
made with Leica UC6 Ultracut ultramicrotome were placed on 200 mesh copper grids. 
Both copper grids, for nanoparticles and macrophages, were examined on FEI Tecnai G2 
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Spirit TWIN electron microscope (Hillsboro, OR) operating at 80kV. Images were acquired 
digitally with AMT imaging system (Woburn, MA). 
3.3.7 MFTC plasma stability 
To determine differences in MFTC plasma stability across species, 100 µL of 
mouse, rat, rabbit, dog, monkey, and human plasma were incubated with 1 µM MFTC at 
37 °C. At 0, 30, and 90 min, 1 mL methanol was added to each sample and vortexed for 
3 min to stop the reaction. For the 0-min time point, 100 µL ice cold plasma was spiked 
with 100-x prodrug spiking solution in 20% DMSO/80% methanol and immediately after, 
1 ml of ice-cold methanol was added. Heat-inactivated plasma was incubated under the 
same conditions and used as a negative control to differentiate chemical vs. biological 
instability. Following the addition of methanol, samples were centrifuged at 15,000 x g 
for 10 min, 10 µl of supernatant was mixed with 80% methanol containing IS, and then 
10 µl was used for liquid chromatography-tandem mass spectrometry (LC-MS/MS) 
analysis. MFTC and FTC concentrations were determined in the supernates by UPLC-
MS/MS.  
3.3.8 Pharmacokinetics 
Male Sprague-Dawley rats (Charles River Laboratories, Wilmington, MA) 
maintained on normal diet were injected IM with FTC or NMFTC at a dose of 45, 75, or 
100 mg/kg FTC-equivalents in the caudal thigh muscle. Blood was collected at 2 hours, 
and days 1, 7, and 14; and tissues, including liver, spleen, lymph nodes, and brain, were 
collected at days 1, 7 and 14.  FTC was quantified by LC-MS/MS with modification of an 
established method [92].  Briefly, 25 µL of plasma samples and a 100 µL of tissue 
homogenates in 90% methanol were spiked with internal standard (15N213C- lamivudine at 
80 ng/ml, final concentration of 8 ng/ml), and extracted with methanol-protein precipitation. 
Plasma and tissue standards were prepared at final concentrations in the range of 0.05-
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500 ng/ml. FTC was quantified by a LC-MS/MS system consisting of a Waters ACQUITY 
H class liquid chromatography system coupled to a Waters Xevo TQ-S micro mass 
spectrometer (Waters Corp., Milford, MA, USA) with an ESI source in positive mode. An 
ACQUITY UPLC® CSH C18 1.7 μm analytical column (2.1mm×100mm, Waters Corp.) 
with an ACQUITY CSH C18 Vanguard column (2.1mm×5mm, Waters Corp.) were used 
for analyte separation. The transition of 247.98 < 129.80 m/z and 233.23 < 114.97 m/z 
were used for FTC and IS quantification. Mobile phase A consisted of 7.5 mM ammonium 
bicarbonate in water (MS grade, Fisher), pH was adjusted to 7.0 with glacial acetic acid 
(ACS grade, Sigma). Mobile phase B was 100% methanol (MS grade, Fisher). The flow 
rate was 0.25 mL/min. 
3.3.9 Cell isolation for FTC-TP extraction 
On each sacrifice day, cells from fresh blood, spleen, and lymph nodes were 
isolated and stored in 70% methanol as previously described [92]. PBMCs from rat blood 
were isolated using Histopaque-1083 according to the manufacturer’s protocol. Briefly, 
blood collected in EDTA tubes was layered on top of 1 mL Histopaque-1083 and 
centrifuged for 30 min at 400 x g at room temperature. PBMCs were then aspirated, 
washed twice with PBS, resuspended in 0.2 mL PBS, and cell number was counted. 
Spleens were cut into small pieces and transferred onto 70 μm nylon cell strainers. 
Spleens were minced using the rubber end of the 3-mL syringe plunger, and cells were 
pushed through the cell strainer with HBSS. Cell suspensions were centrifuged at 200 x g 
for 10 min, and supernatants were discarded. Red blood cells were lysed by resuspending 
the pellet in 1 mL of ACK lysing buffer, followed by incubation for two minutes at 37 °C. 
Samples were neutralized with 10 mL HBSS, centrifuged at 200 x g for 10 min for washing 
twice. For lymph node lymphocyte isolation, rat lymph nodes were collected at each time-
point, and cells were isolated as described for splenocytes, except that lymphocytes did 
not require red blood cell lysis. Both splenocytes and lymphocytes were eventually 
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resuspended in 1 mL PBS and cell numbers were carefully counted. Finally, all cells were 
centrifuged at 400 x g for 10 min and cell pellets were lysed with 200 μl of cold 70% 
Methanol and stored in -80 °C for later TP extraction. All cell counting was performed using 
Invitrogen Countess Automated Cell Counter (Carlsbad, CA). 
3.3.10 FTC-TP quantification 
FTC-TP extraction was performed as described previously [92]. Sep-Pak QMA 
cartridges (360 mg, 37–55 μm) were used to separate FTC-TP from its mono- and di-
phosphate forms. The QMA cartridges were conditioned with 10 mL of 500 mM 
KCl followed by 10 mL of 5 mM KCl. Cell samples in 200 μl of 70% Methanol were loaded 
onto the cartridges and washed with 14 mL of 75 mM KCl. The triphosphate fractions were 
eluted with 3 mL of 500 mM KCl. The pH of the TP fractions was lowered by adding 45 μl 
ammonium acetate buffer (pH 4, 10 mM), and dephosphorylated by adding 3 μl type XA 
sweet potato acid phosphatase. The reaction was allowed to proceed in 37 °C shaking 
incubator for up to 1 hour. The 15N213C-3TC internal standard was added following the 
incubation (10 μl of 5 ng/mL, final concentration of 0.5 ng/mL). Following preconditioning 
with 3 mL Methanol and 3 mL H2O, samples were loaded onto Waters OASIS HLB 
cartridges (60 mg, 30 μm), then washed with 3.5 mL H2O to remove KCl. FTC was then 
eluted with 1.4 mL of Methanol and evaporated under vacuum. Once dry, the residues 
were stored at −20 °C then reconstituted with 100 μl 25% methanol before performing LC–
MS/MS analyses as mentioned earlier 
3.3.11 Statistics and data analyses 
All data are presented as mean ± standard deviation (SD) or standard error of the 
mean (SEM) for in vitro and in vivo studies, respectively. In vitro studies were performed 
using a minimum of three biological replicates. In vivo studies included a minimum of 3 
animals per treatment group. For comparisons of two groups, Student’s t test (two-tailed) 
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was used. For comparison between multiple groups, one-way ANOVA with Bonferroni 
correction were performed. For studies with multiple time points, two-way ANOVA and 
Bonferroni’s post hoc tests for multiple comparisons were performed. Results with P < 
0.05 were considered significant. All data were graphed and analyzed using GraphPad 
Prism 6.0 software (La Jolla, CA). 
3.3.12 Study approvals 
All experimental protocols involving the use of laboratory animals were approved by 
the UNMC Institutional Animal Care and Use Committee ensuring the ethical care and use 
of laboratory animals in experimental research. All animal studies were performed in 
compliance with UNMC institutional policies and NIH guidelines for laboratory animal 
housing and care. Human blood cells were isolated by leukapheresis from HIV-1/2 and 
hepatitis seronegative donors and were deemed exempt from approval by the Institutional 
Review Board of UNMC. 
3.4 Results 
3.4.1 MFTC chemical analyses 
 To overcome challenges associated with the short half-life of hydrophilic 
water-soluble FTC, we created poloxamer-encased hydrophobic drug nanosuspensions 
with enhanced cellular drug uptake and improved antiretroviral efficacy [93]. To perform 
this task a 16-carbon fatty acid palmitoyl chloride was conjugated to FTC to form a 
hydrophobic ester prodrug, MFTC, with a final yield of 90% (Figure 3.1). The chemical 
modifications of FTC were confirmed by (1H) and carbon (13C) NMR spectra (Figure 
3.2A and B, respectively), and FTIR spectroscopy. 1H-NMR spectrum showed peaks 
corresponding to terminal methyl group (CH3R) and repeating methylene (RCH2R) 
protons of the fatty acid chain. 1H NMR (500 MHz, CDCl3): 7.94 (d, J = 6.5 Hz 1H), 
6.27-6.31 (m, 1H), 5.35 (q, J = 4.3 Hz 1H), 4.43 (dd, J = 12.5, 2.9 Hz, 1H), 3.56 (dd, J 
= 12.4, 5.3 Hz, 1H), 3.18 (dd, J = 12.4, 
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3.1 Hz, 1H), 2.40 (t, J = 7.5 Hz 1H), 1.63-1.70 (m, 4H), 1.25 (br, 24H), 0.87 (t, J = 6.9 Hz 
1H). 13C NMR (125 MHz, CDCl3): δ 173.1, 157.9, 157.8, 153.5, 137.1, 135.2, 125.8, 
125.6, 87.4, 84.6, 63.2, 38.9, 34.0, 31.9, 29.8, 29.7, 29.6, 29.4, 29.3, 29.2, 29.1, 24.8, 
22.7, 14.1. MS-ES+ (m/z): calculated for C24H40FN3O4S, 485.25 (100%), 486.28 
(26.0%), 487.27 (4.5%); and found, 486.21[M+H+]. The FTIR spectrum of MFTC (Figure 
3.3) showed the appearance of bands at 2920 and 2860 cm-1 that correspond to C-H 
stretches of the fatty acid chain. Additionally, both palmitoyl chloride and MFTC spectra 
exhibited absorption bands corresponding to the carbonyl group at 1805 and 1745 cm-1. 
XRD analysis revealed distinct diffraction patterns for FTC and MFTC suggesting different 
arrangement of atoms within the crystal lattice of each (Figure 3.4). Esterification of FTC 
decreased the aqueous solubility of the parent drug by 1200-fold (Figure 3.5A). 
Measurement of HIV-1 RT activity in MDMs demonstrated that MFTC did not significantly 
change the EC50 of MFTC (0.033 µM) as compared to FTC (0.079 µM). These results 
indicated that the prodrug is efficiently hydrolyzed into the parent drug (Figure 3.5B). 
3.4.2 NMFTC preparation and characterization 
 NMFTC was prepared by high-pressure homogenization using P407 as the stabilizing 
surfactant. The resultant nanoparticle size, PDI, and zeta-potential were 350 ± 10 nm, 
0.24 ± 0.02, and -20 ± 2 mV, respectively, with an encapsulation efficiency of 85%. Long 
term stability of NMFTC was monitored at 25 °C and 4 °C. Nanoparticle size, PDI, and 
zeta-potential remained within acceptable range (± 10% variability) for at least 10 weeks 
(Figure 3.6A, B). NMFTC particle morphology was predominantly rod-shaped as shown 
by TEM (Figure 3.6C). 
3.4.3 NMFTC-macrophage interaction 
 Treatment with up to 100 µM NMFTC did not affect MDM viability, as determined by 
the CCK-8 assay, after a 24 h exposure (Figure 3.7). This concentration was thus selected 
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for subsequent in vitro studies. Quantitation of intracellular MFTC levels showed that 
NMFTC was readily taken up by MDMs, reaching the highest concentration of 25 nmol/106 
cells at 4 h followed by a rapid prodrug decay over 24 h (Figure 3.8).  In contrast, exposure 
to FTC resulted in minimal detectable intracellular drug levels. Surprisingly, FTC was not 
detected in cells treated with NMFTC. These results led us to quantify intracellular levels 
of the active triphosphate metabolite, FTC-TP. Quantitation of FTC-TP demonstrated 
enhanced intracellular FTC-TP levels after exposure to NMFTC, reaching the highest 
concentration of 75 pmol/106 cells after 8 h, compared to only 10 pmol/106 cells for FTC 
exposure (Figure 3.9A). After 8 hours of NMFTC treatment then removal, intracellular 
FTC-TP levels were detected for up to 10 days (1.5 pmol/106 cells). NMFTC treatment 
resulted in 3-fold higher FTC-TP levels at day 5 (3.2 pmol/106 cells) compared to FTC 
treatments (Figure 3.9B). TEM showed MDM cytoplasm loaded with nanoparticles after 4 
h exposure to NMFTC presumably in endosomal compartments [90, 94] (Figure 3.10).  
3.4.4 Antiretroviral activities 
 MDMs incubated with 100 µM FTC or NMFTC for 8 hours were challenged with HIV-
1ADA at 5-day intervals thereafter. Prior exposure to NMFTC completely inhibited viral RT 
activity analyzed in the cell culture medium when cells were challenged sequentially after 
drug preloading (Figure 3.11). This effect was reduced to 25% inhibition with NMFTC 
when cells were challenged 15 days after drug preloading and to 30% at 24 h with FTC. 
Results were confirmed in adherent cells stained for HIV-1 p24 antigen. No HIV-1 positive 
(brown) cells were observed in cells challenged with HIV-1ADA 10 days after NMFTC 
loading; however, HIV-1 p24+ cells were observed after a 15-day challenge. In contrast, 
HIV-1 p24+ cells were observed by 12 hours following native FTC treatments (Figure 
3.12). 
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3.4.5 MFTC plasma stability 
 To assess the metabolic stability of MFTC in plasma, we incubated MFTC for 90 min 
in plasma from 6 species, namely mouse, rat, rabbit, monkey, dog, and human. MFTC 
rapidly declined in mouse and rat plasma, and within 30 min no detectable prodrug was 
observed. MFTC disappearance was slower in the plasma of other species with % decline 
compared to 0-min at 92% in rabbit, 33% in monkey, 20% in human and 11% in dog after 
90-min of incubation (Figure 3.13A). Prodrug decay was accounted for with formation of 
the parent drug (FTC) as a result of ester bond hydrolysis (Figure 3.13B). 
3.4.6 PK assessments 
 Sprague-Dawley rats were injected IM with either FTC or NMFTC at 45, 75, or 100 
mg/kg FTC-equivalent doses to determine the effect of dose escalation on the PK profile. 
At 2h, FTC plasma levels (Figure 3.14) were several fold higher following FTC treatment 
compared to NMFTC treatment; however, by day 1 FTC concentrations had dropped 
markedly in the FTC treated animals, regardless of dose. On day 1, NMFTC provided 20-
fold higher FTC plasma levels at all 3 doses compared with parent FTC (25, 34, and 52 
ng/mL with FTC; 552, 696, and 1150 ng/mL with NMFTC for 45, 75 and 100 mg/kg 
treatments, respectively), indicating a slow release of FTC from the nanoformulation 
versus immediate release of the parent FTC. At day 7, NMFTC showed 11-, 14-, and 40-
fold higher FTC levels with respect to the 3 doses as compared with parent FTC (0, 3, 1.4 
ng/mL with FTC; 11, 42, and 55 ng/mL with NMFTC). At day 14, plasma FTC 
concentrations were 5-fold lower than the reported IC50 (i.e. 8 ng/mL) and 8-fold lower 
than the IC90 (i.e. 14 ng/mL) in all NMFTC treatment groups. Tissue FTC levels in liver, 
spleen, lymph nodes, and brain are shown in Figures 3.15, 3.16, 3.17, and 3.18, 
respectively. At day 1, NMFTC showed 11- to 28-fold higher FTC levels in all tissues 
compared to parent FTC. In the liver at day 7, NMFTC showed 5-, 2-, and 127-fold higher 
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FTC levels compared to parent FTC at the respective doses (2.6, 14, and 0.6 ng/g with 
FTC; 13, 27, and 76 ng/g with NMFTC). In the spleen at day 7, NMFTC showed 10-, 15-, 
and 10-fold higher FTC levels compared to parent FTC at the respective doses (0, 1.6, 
and 6 ng/g with FTC; 10, 25, and 59 ng/g with NMFTC). In lymph nodes at day 7, NMFTC 
showed 2-, 6-, and 13- fold higher FTC levels as compared with parent FTC at the 
respective doses (17, 6, and 8 ng/g with FTC; 25, 35, and 104 ng/g with NMFTC). In the 
brain at day 7, NMFTC showed 2-, 18-, and 10-fold higher FTC levels as compared with 
parent FTC at the respective doses (1.3, 1, 0.7 ng/g with FTC; 2.7, 18, 7 ng/g with 
NMFTC). At day 14, tissue FTC levels were detectable only in lymph nodes from the 
highest NMFTC dosed treatment group (36.9 ng/g).  
 To determine whether the active triphosphate concentrations in lymphoid cells in vivo 
would be improved by treatment of rats with NMFTC compared to FTC, FTC-TP levels in 
PBMCs, splenocytes and lymph node cells were determined. Intracellular FTC-TP levels 
in PBMCs mirrored the FTC concentrations in plasma. At 2 hours PBMC FTC-TP levels 
were 2-3-fold higher with parent FTC treatment compared to NMFTC treatment (Figure 
3.19). However, on day 1, this was reversed and NMFTC treatment provided up to 2-fold 
higher FTC-TP levels compared to parent FTC (100, 133, and 163 fmol/106 cells with FTC; 
116, 267, and 407 fmol/106 cells with NMFTC). At day 7, FTC-TP levels were 8-fold higher 
with NMFTC compared to parent FTC (6, 7, and 8 fmol/106 cells with FTC; 43, 60, and 64 
fmol/106 cells with NMFTC). Intracellular FTC-TP levels in spleen and lymph nodes are 
shown in Figures 3.20 and 3.21, respectively. As compared to parent FTC, NMFTC 
treatment resulted in 2- to 4-fold higher FTC-TP levels in splenocytes and lymph node 
cells at days 1 and 7, respectively with all doses. FTC-TP levels in spleen at day 1 were 
6-13 fmol/106 cells with FTC and 27-36 fmol/106 cells with NMFTC. These levels 
decreased by day 7 to 2-3 fmol/106 cells with FTC and 6-8 fmol/106 cells with NMFTC, 
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regardless of dose. FTC-TP levels in lymph node cells at day 1 were 4-7 fmol/106 cells 
with FTC and 8-13 fmol/106 cells with NMFTC. FTC-TP levels in lymph node cells dropped 
by day 7 to 1-2 fmol/106 cells with FTC and 3-4 fmol/106 cells with NMFTC regardless of 
dose. At day 14, detectable concentrations of FTC-TP in PBMCs, spleen, and lymph node 
cells were observed following NMFTC treatment, with the highest concentration in lymph 
node cells of animals treated with the highest dose (up to 2 fmol/106 cells). Thus, NMFTC 
provided slower release of the drug in plasma and significantly higher drug levels in 
plasma and tissues for at least 7 days compared to the parent drug. Increasing the dose 
resulted in higher drug levels in plasma and tissues, however, no dose-dependent 
differences in intracellular FTC-TP were observed. 
3.5 Discussion 
Since its introduction in 1996, cART has changed the clinical care landscape for 
HIV patients. These cART regimens have effectively decreased HIV viral load and 
substantially reduced disease morbidity and mortality [95]. However, due to unique viral 
characteristics and disease course, their management requires strict regimen adherence 
[96]. Moreover, rapid viral replication can often result in the emergence of mutations and 
drug resistance [97]. This has driven the development of new classes of drugs and 
alternative drug formulations that allow less frequent dosing while maintaining therapeutic 
drug levels in plasma and tissues.  
LA ART has taken several forms.  One is the development of controlled release 
microparticle carrier systems that rely on drug depot formation at the injection site [98]. 
However, these systems exhibit a tendency to aggregate due to lack of particle 
homogeneity leading to injection site reactions and thus limiting their usage [99]. 
Nanotechnology facilitates creation of formulations capable of crossing biological barriers 
and forming intracellular drug depots.  This allows drug entry into tissues where 
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conventional formulations do not have access followed by subsequent slow release, as 
opposed to macroparticles, which tend to form injection site depots and for which  local 
adverse reactions are very common [99]. 
In the current study, we developed a prodrug nanoformulation of the NRTI FTC to 
extend its apparent half-life and improve distribution to viral reservoir cells. FTC is an 
important component of initial HIV therapy as per recommendations of the International 
Antiviral Society-USA Panel [83]. Furthermore, FTC and TDF in combination have been 
shown to be effective as a PrEP prevention in high risk populations [54]. Therapeutic 
limitations of current FTC include a short plasma half-life, which requires once daily 
administration, and restriction of drug penetrance to viral reservoirs. These limitations 
emphasize the need for a LA parenteral nanoformulated FTC. LA therapeutics utilizing 
hydrophobic prodrugs have been very successful in the clinic for management of psychotic 
disorders [38, 100]. Our group has used similar strategies to develop hydrophobic prodrug 
nanoformulations of HIV integrase inhibitors CAB and dolutegravir that extended their 
antiretroviral efficacy for more than a month [49, 88]. Others have also reported an 
improvement in anti-HIV activity and cellular uptake with different FTC prodrugs; however, 
in contrast to our study, these FTC prodrugs were less hydrophobic, and were not 
delivered as nanoformulations [101]. In the current study, modification of FTC by 
conjugating the 16-carbon fatty acid chain, palmitoyl chloride, markedly increased the 
drug’s hydrophobicity bringing the aqueous solubility from 134 to 0.12 mg/mL. This 
modification allowed for synthesis of stable nanocrystals with high encapsulation efficiency 
[102]. Furthermore, our method formed homogenous rod-shaped nanoparticles. Such 
nanoparticles have been shown to be more readily taken up my macrophages as opposed 
to round-shaped or spherical particles [103-105]. 
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Macrophages are a major HIV reservoir, thus targeting macrophages for effective 
treatment of HIV infection has received considerable attention [106-109]. Moreover, 
macrophages are responsible for sustaining viral load and for spreading virus to other 
tissues [110, 111]. Uptake of NMFTC by MDMs was high and sustained for 10 -15 days, 
indicating the potential of NMFTC to target HIV reservoirs. Furthermore, macrophages 
could potentially be harnessed as a vehicle for drug delivery to tissues where current drugs 
do not have access. Interestingly, exposure of MDMs to NMFTC resulted in inhibition of 
viral replication after challenging the cells with HIV infection as long as 10 days after drug 
preloading. This result was unexpected based on our initial MDM uptake study, where no 
MFTC of FTC was detected by day 1 with 8-hour drug exposure.  However, active FTC-
TP levels showed that detectable levels were retained for up to 10 days after an 8-hour 
pre-exposure, which explained the in vitro efficacy study results. These observations were 
extended to in vivo studies, where several fold higher FTC and FTC-TP levels were 
present for at least 7 days in plasma, tissues, and lymphoid cells after a single NMFTC 
injection compared to treatment with FTC. Interestingly, the rate of hydrolysis of the 
prodrug and release of parent FTC was much slower in human plasma compared to rat 
plasma. These results suggest that this prodrug nanoformulation could be even more 
effective in prolonging drug residence time and efficacy in humans, due to differences in 
plasma esterase activities among species [112]. 
In summary, these studies describe the synthesis of a LA nanoformulation of a 
hydrophobic derivative of FTC and demonstrate that it has the potential to result in 
extended inhibition of HIV replication in macrophages. Higher drug levels and distribution 
in reticuloendothelial system and brain for longer period indicates that development of 
nanoparticles for anti-HIV drugs is a promising approach for improving patient adherence, 
long term efficacy, prevention and treatment of HIV infection. Creation of hydrophobic 
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prodrugs and their incorporation into nanoparticles may provide an effective way to 
facilitate the generation of effective and LA anti-HIV therapeutics. 
3.6 Conclusions 
We have demonstrated that a palmitoylated ester prodrug of FTC can extend in 
vivo drug concentrations to provide improved antiretroviral activity. The increased drug 
hydrophobicity facilitated formation of a P407-stabilized lipophilic nanoformulation with 
high drug loading efficiency. This enhanced drug uptake and antiretroviral activity in 
MDMs. Retention of intracellular FTC-TP provided extended antiretroviral activity of 
NMFTC in MDMs. Interestingly, following a single IM injection, FTC concentrations were 
maintained in blood, reticuloendothelial tissues, and brain for at least 7 days at significantly 
higher levels with NMFTC as compared with the parent drug. These results paralleled 
intracellular FTC-TP levels in PBMCs and in cells isolated from spleen and lymph nodes. 
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3.7 Figures and tables 
 
 
Figure 3.1 MFTC synthesis reaction. Schematic for modification of FTC with a 16-
carbon palmitoyl fatty acid chain. 
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Figure 3.2 (A) 1H and (B) 13C- NMR spectra of MFTC in CDCl3. Additional peaks 
corresponding to the protons and carbon atoms of the fatty acid chain confirmed 
derivatization of FTC.  
A 
B 
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Figure 3.3 MFTC FTIR spectrum. Highlighted in dashed circles on the FTIR spectrum of 
MFTC are the absorption peaks at 2920 and 2860 cm-1 that correspond to CH2-CH2 
stretches of the fatty acid chain and at 1745 cm-1 that corresponds to the carbonyl group 
that is part of the ester bond. 
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Figure 3.4 MFTC XRD spectrum. FTC and MFTC spectra show distinct diffraction 
patterns of both compounds indicating that they are for two different compounds; also, it 
indicates that the chemical modification retained the crystalline nature. 
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Figure 3.5 MFTC aqueous solubility and EC50. (A) Aqueous solubility of FTC and MFTC 
demonstrates decrease in solubility of MFTC (mean ± SD, n = 3; ***P≤0.001). (B) EC50 
was determined in vitro by HIV-1 RT activity assay (0.079 and 0.033 µM for FTC and 
MFTC, respectively) demonstrating the chemical modification did not significantly change 
the antiretroviral activity of FTC. Results were analyzed by nonlinear regression fit (mean 
± SD, n = 3). 
  
A 
B 
60 
 
 
 
 
Figure 3.6 NMFTC stability and morphology. Nanoparticle stability in terms of size, PDI, 
and zeta-potential was measured at (A) 25 °C and (B) 4 °C. (C) TEM showed that the 
nanoparticles are predominantly rod-shaped. Data in A and B are shown as mean ± SD 
(n = 3). 
  
A 
B 
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Figure 3.7 NMFTC cytotoxicity. MDMs exposed to a range of concentrations of either 
FTC or NMFTC demonstrated that NMFTC has no toxicity for up to 100 µM. In contrast, 
FTC is non-toxic for up to 500 µM. Data are shown as mean ± SD (n = 3). 
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Figure 3.8 NMFTC uptake in MDMs. NMFTC was readily taken up by MDMs, with peak 
MFTC after 4 hours (25 nmol/106 cells) and declining thereafter. In contrast, FTC showed 
minimal uptake into MDMs. Data are means ± SD (n = 3).  
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Figure 3.9 Intracellular FTC-TP levels in MDMs. (A) FTC-TP quantitation showed 
significantly higher concentration after exposure to NMFTC over 8 hours. (B) After 8-hour 
exposure, FTC-TP levels retained in MDMS for up to 10 days in significantly higher 
concentrations with NMFTC as compared with FTC. Data are means ± SD (n = 3). 
  
A B 
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Figure 3.10 TEM of macrophage exposed to NMFTC. TEM shows macrophage 
cytoplasm loaded with NMFTC (white clusters) 4-hour after exposure to NMFTC.  
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Figure 3.11 NMFTC antiretroviral activity in MDMs. NMFTC pre-exposure resulted in 
complete inhibition of viral RT activity after HIV-1ADA challenge 10 days post pre-exposure. 
This effect declined to 20% after challenging 15 days post pre-exposure. On the other 
hand, FTC pre-exposure had no effect beyond 1 day. Data are means ± SD (n = 9). 
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Figure 3.12 HIV-p24 antigen staining. Staining MDMs for HIV p24 antigen showed 
results parallel to those for RT activity in Figure 3.11. No staining was found in cells 
challenged 10 days after pre-exposure to NMFTC. In contrast, cells stained positive when 
challenged at day 1 after FTC pre-exposure. 
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Figure 3.13 MFTC plasma stability. MFTC stability was tested in plasma of 6 different 
species. (A) MFTC exhibited variable hydrolysis rate being highest in mouse and rat > 
rabbit > monkey > human > dog. (B) Hydrolysis results were concomitant with FTC 
formation rate in plasma of the same species. 
  
A 
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Figure 3.14 FTC concentrations in plasma. Rats were injected with 45, 75, or 100 mg/kg 
FTC or FTC-equivalent NMFTC. Initially at 2-hour time-point, several fold higher FTC 
concentrations were found in rats injected with FTC. However; this level markedly declined 
by day 1 where NMFTC injection showed significantly higher FTC levels for at least day 
7. At day 14, drug levels were below the limit of detection. Data are means ± SEM (n = 3-
5). 
  
45 mg/kg                                  75 mg/kg                               100 mg/kg 
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Figure 3.15 FTC concentrations in liver. Rats were injected with 45, 75, or 100 mg/kg 
FTC or FTC-equivalent NMFTC. Rats injected with NMFTC showed significantly higher 
drug levels for at least 7 days as compared to rats injected with FTC. At day 14, drug 
levels were below the limit of detection. Data are shown as mean ± SEM (n = 3-5). 
  
45 mg/kg                                  75 mg/kg                               100 mg/kg 
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Figure 3.16 FTC concentrations in spleen. Rats were injected with 45, 75, or 100 mg/kg 
FTC or FTC-equivalent NMFTC. Rats injected with NMFTC showed significantly higher 
drug levels for at least 7 days as compared to rats injected with FTC. At day 14, drug 
levels were below the limit of detection. Data are means ± SEM (n = 3-5). 
  
45 mg/kg                                  75 mg/kg                               100 mg/kg 
71 
 
 
 
 
 
Figure 3.17 FTC concentrations in lymph nodes. Rats were injected with 45, 75, or 100 
mg/kg FTC or FTC-equivalent NMFTC. Rats injected with NMFTC showed significantly 
higher drug levels for at least 7 days as compared to rats injected with FTC. At day 14, 
drug levels were below the limit of detection except with NMFTC injection at 100 mg/kg. 
Data are shown as mean ± SEM (n = 3-5). 
  
45 mg/kg                                  75 mg/kg                               100 mg/kg 
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Figure 3.18 FTC concentrations in brain. Rats were injected with 45, 75, or 100 mg/kg 
FTC or FTC-equivalent NMFTC. Rats injected with NMFTC showed significantly higher 
drug levels for at least 7 days as compared to rats injected with FTC. Data are shown as 
mean ± SEM (n = 3-5). 
  
45 mg/kg                                  75 mg/kg                               100 mg/kg 
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Figure 3.19 FTC-TP concentrations in PBMC. Rats were injected with 45, 75, or 100 
mg/kg FTC or FTC-equivalent NMFTC. Following the same pattern observed in plasma, 
initially at 2-hour time-point, several fold higher FTC-TP concentrations were found in rats 
injected with FTC. However; this level markedly declined by day 1 where NMFTC injection 
showed significantly higher FTC-TP levels for at least day 7. At day 14, FTC-TP levels 
were below the limit of detection. Data are shown as mean ± SEM (n = 3-5). 
  
45 mg/kg                                  75 mg/kg                               100 mg/kg 
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Figure 3.20 FTC-TP concentrations in splenocytes. Rats were injected with 45, 75, or 
100 mg/kg FTC or FTC-equivalent NMFTC. Rats injected with NMFTC showed 
significantly higher FTC-TP levels for at least 7 days as compared to rats injected with 
FTC. At day 14, FTC-TP levels were below the limit of detection. Data are shown as mean 
± SEM (n = 3-5). 
  
45 mg/kg                                  75 mg/kg                               100 mg/kg 
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Figure 3.21 FTC-TP concentrations in lymph nodes. Rats were injected with 45, 75, or 
100 mg/kg FTC or FTC-equivalent NMFTC. Rats injected with NMFTC showed 
significantly higher drug levels for at least 7 days as compared to rats injected with FTC. 
At day 14, drug levels were below the limit of detection except with NMFTC injection at 75 
and 100 mg/kg. Data are shown as mean ± SEM (n = 3-5). 
  
45 mg/kg                                  75 mg/kg                               100 mg/kg 
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Chapter IV. NMFTC Pharmacodynamic 
Evaluation 
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4.1 Abstract 
LA NMFTC showed promise for passively targeting MDMs, improving drug half-
life, and enhancing drug biodistribution into reticuloendothelial and brain tissue as 
described in chapter III. To extend these studies, NMFTC, which target macrophages and 
permits formation of cellular drug depots, was examined using PD evaluation. To date, 
there are two mouse models that have been thoroughly investigated for HIV infection. 
Initial evaluation was done in human peripheral blood lymphocyte (hu-PBL)-reconstituted 
NOD/scid-IL-2Rγcnull (NSG) mice. Because graft-vs-host disease-induced CD4+ T cell 
activation is common in this model, a second murine model, NSG mice reconstituted at 
birth with CD34+ human hematopoietic stem cells (HSC), was used to assess the efficacy 
of NMFTC. Unfortunately, NMFTC did not show significant protection as a PrEP measure 
in hu-PBL mice model. The second humanized mice model was limited because HIV 
challenge required longer periods to establish infection leading to inconclusive results. 
However, there is still potential for NMFTC to suppress HIV infection for longer periods 
than the parent compound. Therefore, repetition of these studies is advised, following 
optimization of the study protocol. 
4.2 Introduction 
Choosing a relevant animal model is a major hurdle, given that HIV infects only 
humans. HIV is specific to human immune cells and specific genetic factors critical for its 
replication. These include binding of HIV to immune cells via the CD4 receptor and co-
receptors CCR5 and CXCR4. Attempts were made to express those receptors in murine 
cells, but these have not yet succeeded, which is due, in part. to absence of many factors 
specific to humans. Furthermore, attempts were made to generate a chimeric strain of HIV 
by modifying the virus itself, specifically using simian/human immunodeficiency virus 
(SHIV) that has been reported to replicate in monkeys [113]. Although this chimeric virus 
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elicits immune responses to vaccine constructs, it is different in the response that was 
produced with HIV infection. Limited successes were seen with some other seemingly 
relevant approaches, such as HIV-encoded gene expression [114]. Therefore, there is a 
great need to generate relevant animal models to study HIV-1 infection. In this context, 
humanized mice models, are reasonable alternatives. 
A humanized mouse model generated by knocking down the Prkdc gene exhibited 
immunodeficiency but with leaky production of T and B cells and high production of natural 
killer (NK) cells. Here, knocking down recombinase activating gene 1 or (AND???) 2 
(Rag1/Rag2) produced xenografts with no leaky B or T cell production. Furthermore, 
mutation of non-obese diabetic (NOD) mice led to a drop in the number of NK cells. 
Additionally, mutation of the interleukein-2 (IL-2) (gamma chain receptor) imposed a lack 
of IL-2 signaling in B and T cells that resulted in a more efficient xenograft. Eventually, 
animals with these combined mutations produced a stable engraftment referred to as 
NOD/scid-IL-2Rγcnull (NSG) mice [115]. These hu-PBL reconstituted mice are prepared by 
injectiion with hu-PBL intraperitonially. These mice show upregulation of human leukocyte 
antigen-DR (HLA-DR) and CCR5 that results in production of xeno-reactive T cells. 
However, due to graft-vs-host disease, these mice are prone to die. Moreover, this model 
is restricted by a lack of hematopoiesis, which limits their use as a chronic infection model. 
Despite these limitations, the ease of this model makes it suitable for acute infection 
studies [116].  
Mice transplanted with human CD34+ HSCs, on the other hand, have become 
promising due to graft longevity and the establishment of chronic HIV infection. These 
immunodeficient mice, when transplanted with HSCs, develop a functional human immune 
system, making them susceptible to an HIV-1 infection exhibiting natural human disease 
progression [117]. 
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4.3 Materials and Methods 
4.3.1 Materials 
PFA, and DAB were purchased from Sigma-Aldrich (St. Louis, MO, USA). Optima 
grade LC/MS water and ACN were purchased from ThermoFisher Scientific (Waltham, 
MA, USA). FITC mouse anti-human CD45, Alexa Fluor 700 mouse anti-human CD3, APC 
mouse anti-human CD4, and BV421 mouse anti-human CD8 were purchased from BD 
Biosciences (San Jose, CA, USA). NMFTC was prepared as described in Chapter III, 
3.3.3.  
4.3.2 PD study in hu-PBL mouse model 
Male 6-8-week-old NOD/SCID/IL2Rγc-/- (NSG) mice (Jackson Labs, Bar Harbor, 
ME, USA) were given intraperitoneal injection with 25 × 106 hu-PBL obtained by 
leukapheresis and centrifugal elutriation. Reconstitution was allowed to establish for 10 
days. Then, mice were given IM injection with FTC or NMFTC at 45 mg FTC 
equivalents/kg. Five days following drug administration, mice were challenged with 104 
50% tissue culture infectious doses (TCID50) of HIV-1ADA by intraperitoneal injections. Mice 
were sacrificed 10 days after viral challenge. The experimental timeline is shown in Figure 
4.1. Peripheral blood was collected in EDTA-coated tubes at days 9 (to confirm PBL 
reconstitution), 15 (before HIV challenge), and 25 (10 days after HIV challenge) for flow 
cytometry analysis of human pan-CD45, CD3, CD4 and CD8 immune cell markers [118]. 
Plasma was collected via centrifugation at 2,000 × g for 5 min at days 10, 21, and 32 for 
drug quantitation by UPLC-MS/MS. At the day of sacrifice, liver, spleen, lung, lymph 
nodes, bone marrow, gut, brain, and kidney were collected for drug quantitation by UPLC-
MS/MS. 
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4.3.3 PD study in CD34+ HSC mouse model 
NSG mice were reconstituted at birth with CD34+ HSCs isolated from umbilical 
cord blood [119]. Reconstituted mice were administered a single IM dose of FTC or 
NMFTC at 45 mg/kg FTC-equivalent. Mice were challenged 2 and 7 days after drug 
treatment with 2 × 104 TCID50 of HIV-1ADA by intraperitoneal injection. Mice were sacrificed 
2 weeks after HIV-1 challenge, and blood and plasma were collected to determine drug 
levels and viral load, respectively. The experimental timeline is shown in Figure 4.2. 
Plasma was used for quantifying viral load (measurements of HIV-1 RNA) using the Roche 
Amplicor and Taqman-48 system. 
4.3.4 Viral load and HIV RNA and DNA PCR determination 
HIV-1 viral load was analyzed in day 25 plasma samples using the Roche Amplicor 
and Taqman-48 system with HIV-1 kit V 2.0 according to the manufacturer’s instructions 
(Roche Diagnostics, Indianapolis, USA). At the day of sacrifice, liver, spleen, lung, lymph 
nodes, gut, brain, and kidney were collected for viral RNA and DNA quantitation by semi-
nested real-time polymerase chain reaction (PCR) [120] and for immunohistochemical 
staining for HIV-1p24 antigen as described previously [52]. 
4.4 Results 
4.4.1 Viral restriction in hu-PBL mouse model 
Since NMFTC demonstrated macrophage targeting and accumulation in 
reticuloendothelial tissues, spleen tissue was analyzed by PCR to obtain preliminary HIV-
1 RNA counts. Mice challenged 5-days post drug administration showed 5 out of 6 animals 
harboring HIV-1 RNA comparable to infected positive controls (Figure 4.3). Mice 
challenged 1-day post drug administration were not analyzed, as many animals died 
during the study, most likely due to graft-vs-host disease, which reduced the statistical 
power of that group of animals. 
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4.4.2 Viral restriction in CD34+ HSC mouse model 
 In this model, detection of plasma viral load in NMFTC injected animals showed 
complete protection in mice challenged with HIV-1 at 2 days post drug administration while 
FTC showed about 60% protection (Figure 4.4). In mice challenged at day 7 post 
treatment, 3 out of 5 animals were protected in both FTC and NMFTC treated groups. 
However, 3 out of 5 HIV-1 infected positive controls also did not show detectable viral load 
(Figure 4.5) which rendered our results inconclusive. 
4.5 Discussion 
No mouse model perfectly reflects human disease, so we used both hu-PBL and 
CD+ HSC-reconstituted mouse models. Unfortunately, viral restriction as performed in hu-
PBL mice failed to provide protection against viral challenge, as shown by detectable 
spleen viral load. This likely reflects enhancement of viral susceptibility in the animals 
based on the large numbers/percentages of activated lymphocytes due to xenoreactivity 
leading to graft-vs-host disease, timing of human cell reconstitution, larger viral challenge, 
route of viral challenge, and a monotherapy approach [121-124]. CD34+ HSC-
reconstituted NSG mice better reflect human biology, because there is no graft-vs-host 
disease and the reconstitution contains monocyte-macrophages, as well as CD4+ and 
CD8+ T lymphocytes [125]. To these ends, this model was used, expecting better results 
or to confirm results of the prior study. Indeed, cells were quiescent prior to viral challenge. 
Most importantly, NMFTC-treated HSC-NSG mice demonstrated plasma viral load below 
the limit of detection in all animals for two days after HIV-1 challenge following a single 
nanoparticle injection. Due to drug-related limitations, however, the time allotted to 
establish viral infection was not sufficient, as seen in HIV-infected control animals Based 
on the intrinsic properties of drug stability, in vitro studies in MDMs, and PK profile, such 
chemical prodrug modifications led to the formation of a second drug reservoir beyond the 
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injection site, inside macrophages. Such improvements are likely to reflect on drug PD; 
however, modifications to the current protocol, for example increasing the dose, are 
required.  
4.6 Conclusions 
Two different animal models were used to evaluate viral restriction after a single 
NMFTC IM injection. Unfortunately, majority of hu-PBL reconstituted mice that were 
challenged one day after drug injection died due to the limitations of this model failing this 
study. To overcome these limitations, we moved forward to use CD34+ HSC reconstituted 
mouse model. However, our proposed protocol, that was based on the PK profile of 
NMFTC, did not give us conclusive results. We posit that further understanding and 
amendment of the protocol will improve future studies. 
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4.7 Figures 
 
 
Figure 4.1. Hu-PBL reconstituted mouse model study scheme. Animals were injected 
with hu-PBL and reconstitution allowed to occur for 10 days. After 45 mg/kg FTC-
equivalent dose administration at day 0, animals were challenged with HIV-1ADA at day 1 
or 5. Ten days after challenge, animals were sacrificed, and blood and tissues were 
collected for analyses. 
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Figure 4.2. CD34+ HSC reconstituted mouse study scheme. Animals were injected 
with 45 mg/kg FTC-equivalent dose at day 0. Then, animals were challenged with HIV-
1ADA at day 2 or 7. One week after challenge, blood was collected to determine CD4 and 
CD8 levels, viral load, and drug levels. Two weeks after challenge, animals were 
sacrificed, and blood and tissues were collected for analyses. 
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Figure 4.3 Viral load in spleen. Spleen tissues obtained from hu-PBL reconstituted mice 
challenged 5 days post drug administration. NMFTC did not show significant protection 
and results with NMFTC were comparable to FTC-treated or HIV-infected untreated 
controls.  
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Figure 4.4 Plasma viral load after day 2 challenge. Plasma samples obtained from 
CD34+ HSC reconstituted mice challenged 2 days post drug administration were analyzed 
for viral RNA. NMFTC showed complete protection as compared to only 4 out of 7 animals 
protected by FTC. However, 3 out of 5 positive controls did not show viral loads. 
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Figure 4.5 Plasma viral load after day 7 challenge. Plasma samples obtained from 
CD34+ HSC reconstituted mice challenged 7 days post drug administration were analyzed 
for HIV-1 RNA. NMFTC showed 3 out of 5 animals protected similarly to FTC. However, 
3 out of 5 positive controls did not show viral loads. 
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Chapter V. Conclusions and Future 
Directions 
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5.1 Conclusions 
Drugs formulated as nanocrystals hold promise based on their characteristic 
properties of size and crystalline nature to facilitate prolonged particle stability, higher 
dissolution rate, and improved transit across biological barriers. Selection of the excipient 
for making aqueous suspensions of nanocrystals is crucial to ensure particle integrity 
during storage and to avoid drug-related adverse reactions. Also, optimization of the 
manufacturing process is essential to ensure scalability. Therefore, we screened multiple 
poloxamers, due to their reported safety and success in pharmaceutical and biomedical 
industries. Although each poloxamer has unique physical properties, they did not show 
significant differences in terms of particle stability and MDM uptake and retention. Notably, 
P407 showed the highest uptake and retention in MDMs; therefore, it was chosen for 
further studies. High-pressure homogenization successfully prepared poloxamer-encased 
ATV nanosuspensions. However, purification of this nanoformulation using differential 
centrifugation led to particle aggregation that posed a major challenge in resuspending 
the particles for initial size distribution studies. Direct manufacture, on the other hand, 
resulted in stable and scalable particle formation. 
Nanoformulation of the modified FTC prodrug, NMFTC, has the potential to 
overcome the limitations associated with the parent drug. In addition to prolonged shelf 
life, NMFTC exhibited the ability to target viral reservoirs and also longer duration as 
compared to parent FTC. This was demonstrated by higher drug uptake by macrophages, 
longer circulation time, and higher drug biodistribution in reticuloendothelial tissues along 
with higher intracellular FTC-TP concentrations. However, translation of these results into 
viral restriction in animal models requires thorough understanding of the available HIV-1 
infection models and optimization of the study protocol accordingly. 
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5.2 Challenges and future directions 
The current project has provided improvements in the PK profile of FTC and 
multiple steps forward toward making LA ART formulations of NRTIs. Further 
improvements are needed to extend the PK profile beyond 7 days. This challenge can be 
tackled by combining ligand-based active targeting to HIV reservoirs. Preliminary studies 
in our laboratory have demonstrated that incorporation of FA on the nanoparticle could 
further improve macrophage uptake [50]. Other targeting ligands that target macrophages 
or CD4+ cells, such as hyaluronic acid [126], tuftsin [127], gp120 peptide [128], and others, 
are currently being tested.  
LA formulations and devices are being developed to provide sustained release 
ART for prevention and treatment of HIV-1 infection. Ideal drug candidates for LA delivery 
require extremely potent and hydrophobic molecules. However, most ARVs used in 
combination therapy are either too hydrophilic or require high dosage, limiting their 
potential transition into LA agents. Recent advances in prodrug and nanotechnology 
approaches present an attractive option to overcome the undesirable properties of existing 
ARVs. While ester prodrugs of NRTIs such as MFTC represent a first step towards 
extending the half-life of hydrophilic compounds, another strategy, known as ProTide, can 
be investigated to further enhance drug potency and to sustain active triphosphate levels 
at restricted sites of infection. The ProTide strategy is based on delivery of a 
monophosphate derivative of an NRTI, bypassing the rate-limiting first phosphorylation 
step. Furthermore, this can be coupled with conjugation of fatty acid esters to make LA 
formulations, as we have shown in the current study. 
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